Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 5/20 | 0.39 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | EPRS1 | P07814 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ASPH | Q12797 | 1/20 | 0.36 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.36 |
| ▸ | HAAO | P46952 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1511662 | 1.00 | CYP1A2 (0.39) | CYP1A2MYCGPR17RXFP1EPRS1 | |
| SCHEMBL17040439 | 0.84 | SMN1; SMN2 (0.38) | KDM4E | |
| SCHEMBL29562032 | 0.84 | EPRS1 (0.40) | CYP1A2MYCRXFP1EPRS1LCK | |
| SCHEMBL30484055 | 0.84 | SMN1; SMN2 (0.38) | KDM4E | |
| SCHEMBL206341 | 0.84 | EPRS1 (0.40) | CYP1A2MYCRXFP1EPRS1LCK | |
| SCHEMBL27346257 | 0.82 | ALDH1A1 (0.39) | — | |
| SCHEMBL3540940 | 0.81 | CYP1A2 (0.44) | CYP1A2GPR17TSHRLCKFYN | |
| SCHEMBL1251359 | 0.81 | CYP1A2 (0.44) | CYP1A2MYCRXFP1EPRS1TSHR | |
| SCHEMBL22219524 | 0.79 | SOS1 (0.44) | MYCTSHRKDM4E | |
| SCHEMBL31135335 | 0.79 | SOS1 (0.44) | MYCTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703358-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | China Pharmaceutical University (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260034126-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4648777-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024222614-A1 | HETEROCYCLIC GSPT1 DEGRADATION AGENT | 北京诺诚健华医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | CYP1A2 74/4885MYC 3670/4885GPR17 3905/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | CYP1A2 74/4885MYC 3670/4885GPR17 3905/4885 |
| US-20260034126-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 1996/4885MYC 252/4885GPR17 4384/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CYP1A2 3908/4885MYC 4304/4885GPR17 1500/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | CYP1A2 72/4885MYC 3687/4885GPR17 3868/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | CYP1A2 79/4885MYC 3602/4885GPR17 3975/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | CYP1A2 84/4885MYC 4054/4885GPR17 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.